Kos faces possible Nasdaq delisting

By Lisa Kerner

Charlotte, N.C., Aug. 16 - Kos Pharmaceuticals, Inc. said it will request a hearing before a Nasdaq Listing Qualifications Panel regarding the company's non-compliance with the filing requirements for continued listing as set forth in Marketplace Rule 4310(c)(14).

The company's filing of its 10-Q quarterly report for the quarter ended June 30 is delayed, according to a news release.

Pending a decision by the panel, Kos shares will remain listed on the Nasdaq Stock Market.

An internal review of documents related to the grant and exercise of options from Jan. 1, 1997 to the present is ongoing. The company is also cooperating with The Securities and Exchange Commission to supply documents related to the review.

Kos is a Cranbury, N.J., specialty pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.